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metabolism
SoHvI HöRKKO, MARKKU J. SAVOLAINEN, KARl KERVINEN, and Y. ANTERO KESANIEMI
Department of internal Medicine and Biocenter Ouln, Unirersizy of Oulu, On/u, Finland
Carbamylation-induced alterations in low-density lipoprotein metabo-
lism. Low-density lipoprotein was derived from carbamyl (carbamyl-
LDL) by incubating LDL in potassium cyanate (KCNO). The propor-
tion of free amino groups in the carbamyl-LDL was negatively
correlated (r =
—0.95) with the time of incubation in potassium cyanate(ranged from 5 to 360 mm). The carbamylation did not change the
chemical composition or the flotation characteristics of the LDL
particles. However, the electrophoretic mobility of carbamyl-LDL was
distinctly increased with the extent of carbamylation. The carbamyl-
LDL had substantially decreased binding to the LDL apoB/E receptors
of the bovine adrenocortical membranes when compared to the control-
LDL. The reduced binding was already observed when only 9% of the
free amino groups were derived from carbamyl. A minor carbamylation
of LDL (less than 20% of the free amino groups) decreased the in vivo
clearance of LDL from rabbit plasma. However, when more than 20%
of the free amino groups were derived the carbamyl-LDL had acceler-
ated clearance compared to the control-LDL. LDL isolated from
uremic patients was cleared in rabbits at a slower rate than LDL
isolated from a control subject. Providing that carbamylation of LDL
could also occur in vivo resulting in similar alterations of the LDL
binding to the LDL B/E receptors, as observed in the present study, the
uremia-related accelerated atherosclerosis could have one additional
mechanistic explanation.
these individuals. Several modifications of LDL such as acetal-
dehyde, formaldehyde and glucose derivatization considerably
alter the metabolism of LDL particles both in vitro and in vivo
[3—5]. Condensation of urea-derived cyanate with the lysine
residues of various proteins such as apolipoprotein B (apo B)
could also occur in uremic patients. In fact, this kind of
carbamylation is known to affect the hemoglobin of uremic
subjects [6].
The present study was designed to evaluate how carbamyla-
tion of LDL affects LDL metabolism. Specifically, the follow-
ing questions were addressed: (I) does the in vitro carbamyla-
tion of LDL change the chemical composition or physical
properties of the LDL particles; (2) does LDL carbamylation
affect the specific apoB/E receptor binding of LDL; (3) how
does the carbamylation of LDL alter LDL metabolism in vivo,
and (4) is the in vivo metabolism of LDL isolated from uremic
patients different from that isolated from control individuals?
Methods
LDL isolation
Patients with chronic renal failure are at increased risk for
cardiovascular atheromatous diseases. In fact, half of the
deaths among long-term hemodialysis patients seems to be due
to atherosclerosis, mainly by myocardial infarcts and cere-
brovascular accidents [I].
One of the causes for the advanced risk for atherosclerosis in
patients with chronic renal failure is the seemingly abnormal
lipoprotein profile. The serum (ipoprotein phenotype in many
uremic patients corresponds to type IV hyperlipidemia: an
increase in serum triglycerides in very low density lipoprotein
(VLDL) and low density lipoprotein (LDL), while cholesterol
content in high density lipoprotein (HDL) is decreased [21.
Usually, the cholesterol levels of the most atherogenic lipopro-
tein, LDL, are not markedly increased. However, it is possible
that uremic patients have qualitative alterations in LDL which
could contribute to the high incidence of atherosclerosis in
Blood was drawn from healthy voluntary human subjects in
the fasting state. Blood samples were collected into sterile
EDTA containing tubes and plasma was separated. LDL was
isolated by the method of Lindgren et al [7]. The density of
plasma was first adjusted to 1.019 g/ml with sterile NaCl-NaBr
solution and ultracentrifuged at 59000 rpm and + 15°C for 18
hours (Beckman 60 Ti rotor and Beckman L8-60M ultracentri-
fuge, Beckman Instruments, Inc., Palo Alto, California, USA).
LDL was flotated apart from the remaining infranatant by
adjusting the density to 1.063 g/ml and ultracentrifuging at 59000
rpm for 18 hours.
Finally, the LDL was washed in another NaCI-NaBr solution
(density 1.070 g/ml) ultracentrifuging the preparation at 35000
rpm in a Kontron TFT 45.6 rotor (Kontron Instruments, Zurich,
Switzerland) for 18 hours. Before further use the isolated LDL
was dialyzed against 0.15 M NaCI solution containing 0.01%
EDTA, pH 7.4 (EDTA-saline).
LDL carbamylation
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The isolated LDL was carbamylated with potassium cyanate
(KCNO) [8]. Isocyanic acid from KNCO binds covalently to the
free lysine residues of human LDL forming carbamyl modifi-
cation [8], The LDL was diluted with 0.3 M sodium borate
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buffer (pH 8.0) to 1.5 times the original volume and 20 mg of
potassium cyanate was added to I mg of LDL protein. The
mixture was incubated at + 37°C for various lengths of time (5 to
360 mm) depending on the extent of modification desired.
Excess KCNO and buffer were removed by dialyzing the
carbamylated LDL in 10 liters of EDTA-saline. The control-
LDL was incubated under identical conditions except for the
omission of potassium cyanate.
Low density lipoprotein analysis
Cholesterol and triglyceride concentrations (enzymatic cob-
rimetric methods, kits of Boehringer, Mannheim GmbH, cata-
logue nos. 236691 and 701912, respectively) in the carbamyl-
LDL and control-LDL were determined using a Gilford
IMPACT 400E Clinical Chemistry Analyzer (Gilford Instru-
ments Laboratories Inc., Oberlin, Ohio, USA). LDL protein
concentrations were measured by the method of Lowry et al
[9]. The trinitrobenzenesulfonic acid (TNBS) coborimetric
method [10] was used to determine the amount of free amino
groups in carbamyl-LDL and control-LDL.
Lipoprotein electrophoresis
Electrophoresis for each LDL preparation was carried out
with Corning Agarose Electrophoresis System using 0.05 M
Corning Universal Barbital Buffer containing 0.035% EDTA
(pH 8.6), a constant voltage 90 V for 35 minutes and Fat Red 7B
stain (Corning Agarose Electrophoresis system, Corning Med-
ical, Palo Alto, USA).
Dot-blot assay for LDL receptor
Bovine adrenal glands were obtained 30 minutes after slaugh-
ter and placed in ice-cold buffer (150 mrsi NaCI, 1 mivi CaCI2, 10
mM Tris and 0.5 mrt PMSF, pH 7.5). Membranes were pre-
pared as previously described by Kovanen, Brown and Gold-
stein [11] and stored at —70°C until use. Each membrane pellet
was suspended in 50 mivi NaCI, 1 mivi CaCI2 and 20 mit Tris (pH
7.5) by pressing through a 22-gauge needle prior to the assay.
The suspension was sonicated for 20 to 30 seconds and the
protein concentration was determined as described above.
The assay was performed by the method of Maggi and
Catapano [12] using a microfiltration apparatus (Bio-Dot micro-
filtration apparatus, Bio-Rad Laboratories, Richmond, Califor-
nia, USA) for the dot-blots. Membranes were applied to the
nitrocellulose in a volume of 100 jsl (10 to 20 sg protein per dot)
and the wells were washed with 150 uI buffer containing 50 mM
Tris-maleate, 2 mrvi CaCl2 and 40 mti octyl-glucocide (pH 6).
The nitrocellulose was then removed from the apparatus and
incubated for 60 minutes in 0.01 M Tris, 50 mivi NaCI, 2 mM
CaCI2 containing 3% bovine serum albumin (pH 8.0). The
incubations with iodine-125 labelled LDL ('251-LDL) and 50-
fold excess of unlabelled carbamyl-LDL or control-LDL were
carried out in the same buffer for 60 minutes at room tempera-
ture. The incubation was followed by three washes with the
same buffer. The radioactivities of the dots were determined
with a LKB Wallac 1282 Compugamma Universal Gamma-
counter (Wallac Oy, Turku, Finland).
lodination of LDL
For the in vivo rabbit injections the isolated LDL was
iodinated before the carbamylation. The LDL was divided into
two aliquots: one labelled with iodine-125 (1251) and the other
with iodine-l31 (''I) by the iodine monochboride method of
McFarlane [13] as modified by Bilheimer, Eisenberg and Levy
[14]. A column chromatography (Pharmacia Columns PD-b
Sephadex G-25M, Pharmacia, Uppsala, Sweden) and EDTA-
saline dialysis were used to remove excess free radioiodine.
Precipitation with 10% trichboroacetic acid (TCA) showed that
98.1 1.8% (mean SD) of 125J counts and 99.7 0.8% of I
counts were bound to protein. The extent of lipid labeling was
determined with a chloroform-methanol solvent (2:1) using the
method of Folch et al [15]. The lipid labeling averaged 9.3
2.9% for 1251 and 9.1 2.7% for ''I
For the LDL receptor assay (see above) the isolated LDL
was labeled with 1251 so that a very high specific activity was
obtained (244 to 866 cpm/ng).
Animals
New Zealand White rabbits (3 to 5 kg) were used in the
studies. The animals were individually caged and had free
access to water and food (Astra Ewos commercial rabbit feed).
The rabbits were given K! 10 mg/day two days before and
throughout the study.
Preparation of carbamylated and control LDL for in vivo
rabbit injection
After dialysis radiolabeled carbamyl-LDL and control-LDL
preparations were centrifuged at 3300 x g for 10 minutes (+4°C)
and the supernatant was passed through a 0.22 urn millipore
filter. The radioactivity was determined from iodinated car-
bamyl-LDL and control-LDL preparations, and an amount of I
to 6 uCi of both preparations were mixed and the final solution
again passed through a 0.22 urn millipore filter. To avoid LDL
self-irradiation the rabbit injections were carried out promptly
after the LDL iodination and carbamylation. Each preparation
was injected simultaneously into two rabbits. Each rabbit was
used only once for the in vivo study, because, according to our
experience, the reinjection of any human LDL into the rabbits
results in an extremely abnormal clearance of the preparation,
possibly due to the immunization of the animals against human
LDL protein.
Study protocol and sample analysis for in vivo rabbit
injections
The preparations containing radiolabeled carbamyl-LDL and
control-LDL were injected into a marginal ear vein. Two
milliliter blood samples were obtained at 5, 10, 15, 30 and 60
minutes and 2, 4, 6, 24 and 36 hours from the opposite ear vein.
The total plasma radioactivity was determined in each sample.
Aliquots of plasma samples up to one hour were precipitated
with 10% TCA to demonstrate whether or not the radiolabel
remained protein bound in plasma. Over 94% of both the
iodinated carbarnyl-LDL and control-LDL counts were TCA-
insoluble.
To exclude the effect of the conditions of the carbamylation
on LDL metabolism, the LDL was divided into two aliquots,
one of which was kept at +4°C after the radiolabeling and
dialysis (native-LDL) and the other was incubated with 0.3 M
sodium borate buffer in the absence of potassium cyanate
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(control-LDL) as described above. The catabolism of native-
LDL was compared to that of control-LDL.
Clearance of LDL isolated from uremic patients and a
control subject
In this experiment LDL (d 1.019 to 1.063 g/ml) was isolated
from five volunteer uremic patients who were on maintenance
hemodialysis and from one healthy volunteer control subject as
previously described. All the uremic patients and the control
subject were free of diabetes mellitus, thyroid disease and
hepatic disease. The total plasma cholesterol concentration of
the uremic patients was 4.99 1.72 mmol/liter (mean SD) and
triglyceride concentration 2.34 1.45 mmol/liter. The isolated
uremic-LDL and the control-LDL preparations were iodinated
with 125! and 1311, respectively, also as previously described.
Each pair of the radiolabeled uremic-LDL and control-LDL
preparations were then injected simultaneously into two rab-
bits. The catabolism of the uremic-LDL was compared to that
of the control-LDL.
Kinetic analysis
The fractional catabolic rates (the fractional catabolic rate,
FCR, defined as the intravascular pooi of LDL catabolized per
hour) for the carbamyl-LDL, the uremic-LDL and control-LDL
were calculated from the plasma decay curves using the Mat-
thews method as described in our several previous LDL turn-
over studies [3, 5, 16]. In brief, two exponential equations were
fitted to each plasma decay curve using an interactive curve-
peeling program (W.F. Beltz and T.E. Carew, unpublished
method) on a VAX-VMS Computer.
Statistical analysis
Linear regression analysis was used to determine correlation
coefficients between the incubation time with KCNO and the
percentage of free amino groups in carbamyl-LDL.
Results
Chemical composition and physical properties of carbamyl-
LDL
The cholesterol:triglyceride and the protein:cholesterol ratios
of isolated LDL incubated for various time intervals in KCNO
are shown in Table 1. Carbamylation did not change the
chemical composition of the LDL particles when compared to
the control-LDL and the native LDL.
Free amino groups were determined in the carbamyl-LDL
preparations to study the derivation of LDL apolipoprotein B.
The percentage of free amino groups in the carbamyl-LDL
(range from 97% to 26%) (Table 1) showed a negative correla-
tion (r =
—0.95) with the incubation time in potassium cyanate
(range from 15 to 360 mm).
LDL flotation characteristics were examined by subjecting
the carbamyl-LDL and the control-LDL preparations to ultra-
centrifugation. 96.5 2.4% (mean SD) of the carbamyl-LDL
and 97.4 1.0% of the control-LDL flotated in the originally
isolated density region. Over 93% of the carbamyl-LDL iso-
lated from rabbit plasma samples up to one hour after the
injection flotated within the LDL density range. Also 54% of the
carbamyl-LDL and 45% of the control-LDL from one to four
hours, and 40% of the carbamyl-LDL and 39% of the control-
Table 1. Chemical composition and the percentage of free amino
groups in carbamyl derivatized LDL preparations
Time of
incubation in
KCNO mm
Free amino
groups %
LDL protein:
cholesterol
ratio
LDL cholesterol:
triglyceride ratio
15 97 0.50 8.48
30 86 0.51 8.78
45 77 0.51 8.47
60 72 0.49 8.05
120 56 0.47 8.32
360 26 0.47 8.24
ControlLDLa 100 0.54 8.56
Native-LDL 100 0.52 8.87
Control-LDL was prepared identically to the carbamylated LDL
incubated for 360 minutes, except that KCNO was omitted from the
incubation medium.
LDL from four to seven hours after the injection flotated within
the LDL density range.
Agarose gel electrophoresis results for the LDL preparations
incubated for various time intervals in KCNO (15, 30, 45, 60,
120 and 360 mm) are shown in Figure 1. The electrophoretic
mobility of carbamylated LDL increased linearly with the
incubation time in KCNO.
Binding of carhamylated LDL to LDL receptors
Figure 2 demonstrates the effect of LDL carbamylation on
the LDL binding properties to the LDL apoB/E receptors on
the bovine adrenocortical membrane assay. A slightly carba-
mylated LDL (91% amino groups free) already had distinctly
decreased binding to the LDL receptors when compared to the
control-LDL. The ability of the carbamyl-LDL to bind to the
receptors decreased as the extent of the carbamyl derivation of
the LDL increased. The control-LDL was able to prevent
'251-LDL binding to the receptors to the same extent as the
native LDL (data not shown).
In vivo catabolism of carhamyl-derived LDL preparations
The decay curves for three different carbamyl-LDL and
control-LDL preparations are shown in Figure 3. A slight
carbamylation of LDL (93% of amino groups free) decreased
the FCR for LDL apolipoprotein B from 0.126 pools/hr to 0.046
pools/hr (Fig. 3A). However, when LDL was more heavily
carbamytated (80% and 66% amino groups free; Fig. 3B and C,
respectively) the clearance of the carbamyl-LDL compared to
the control-LDL was substantially accelerated.
The fractional catabolic rates for all the control-LDL and
carbamyl-LDL preparations are shown in Table 2. The LDL
preparations with a mild carbamylation were catabolized at a
slower rate (mean value —59.4%) from the rabbit plasma than
the control LDL (Table 2). In contrast, the LDL preparations
with moderate and extensive carbamylation were cleared at a
faster rate (+40.2 and +251.0%, respectively) than the control-
LDL (Table 2). These changes between the fractional catabolic
rates for the carbamyl-LDL and for the control-LDL were
detected despite the fact that the ability of various rabbits to
catabolize the control-LDL varied eightfold from 0.034 to 0.254
pools/hr. The wide variation of LDL clearance of the control-
LDL among the rabbits was related to the variation of plasma
cholesterol concentration in these animals. In fact, the FCR for
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Fig. 1. Agarose gel elect rophoresis for LDL preparations. The anode is at the top of the Figure. Lipoproteinsapplied were as follows: native-LDL
(1), control LDL (2), carbamyl-LDL preparations with 97, 86, 77, 72, 56, and 26% of amino groups free (3 to 8, respectively).
1251-LDL, g/m/ in incubation medium
Fig. 2. Binding of the carbamylated LDL to adrenocortical meni-
branes. The curve for control-LDL (•) shows the percent of inhibition
of binding on the '251-LDL to the receptors when 50-fold excess of
unlabeled control-LDL was added to the incubation medium. The other
curves show the inhibition of the binding of the 125 1-LDL when
carbamyl-LDL with 91% (v), 88% (V), 87% (la), or 81% (•) ofamino
groups free were added. Each point is the mean of triplicate
determinations.
the control-LDL was negatively correlated (r = —0.64. P <
0.01) with the total plasma cholesterol concentration of the
rabbits among all the studies.
The decay curves for the control-LDL and the native-LDL
were identical (Fig. 4), showing that the incubation conditions
did not alter in vivo catabolism of the control-LDL.
In vivo catabolism of LDL isolated from uremic patients
The catabolism of the LDL isolated from uremic patients
(uremic-LDL) was compared to that of the control-LDL after
the simultaneous injection of the two LDL preparations into
rabbits (Table 3). In general, the FCR values for the uremic-
LDL were somewhat lower than those for the control-LDL,
even though some heterogeneity was observed among the
various preparations. In fact, only one out of the five uremic-
LDL preparations was catabolized at a faster rate than the
control-LDL preparation.
Discussion
The major finding of the present study is that the clearance of
LDL is altered when LDL is carbamylated in vitro. An exten-
sive carbamylation of LDL substantially accelerates the LDL
clearance, whereas a minor derivation seems to decrease the
LDL removal. Furthermore, our findings indicate that the
carbamyl modification affects the free amino terminals in LDL
apoprotein B, resulting in a reduced binding of the carba-
mylated LDL to the LDL apoB/E receptors. Also, our prelim-
inary studies show that LDL isolated from uremic patients are
cleared in vivo from rabbit plasma at a reduced rate when
compared to normal LDL.
Different covalent modifications of free amino residues of
LDL apolipoprotein B have previously been shown to alter
LDL metabolism. Glucose-modified LDL has decreased catab-
olism in both the rabbit [171 and humans 5], Reductive meth-
ylation of LDL with formaldehyde has been shown to delay the
LDL catabolism in rats and monkeys [4], rabbits [18] and
guinea pigs [17]. The decreased catabolism of LDL modified
with glucose or formaldehyde is due to the inability of the
modified LDL to use the high affinity apoB/E-receptor depen-
dent pathway [17]. In accordance with these findings, our data
suggest that reduced clearance of the slightly carbamylated
LDL is due to the inability of the carbamyl-LDL to use the
LDL apoB/E receptor-mediated pathway. In contrast to the
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Fig. 3. Decay curves for three various
carbwnyl-LDL derivations (A) and control-
LDL (L). A. Carbamyl-LDL preparation were
93% of amino groups free. B. Carbamyl-LDL
preparation with 80% of amino groups free. C.
Carbamyl-LDL preparation with 66% of
10 20 30 10 20 30 10 20 30 amino groups free. FCR = fractional catabolic
rate.
Table 2. Fractional catabolic rates (FCR, pools/hr) for the carbamyl-LDL and the control-LDL preparations, and the percentage of the FCR
value of the carbamyl-LDL relative to the corresponding control-LDL
Rabbit no.
Free amino
groups %
FCR for
carbamyl-LDL
FCR for
control-LDL
FCR
change %
Mild carbamylation
I 93 0.032 0.104 —69.2
2 93 0.046 0.126 —63.5
3 83 0.031 0.057 —45.6
Mean sn 90 6 0.036 0.008 0.096 0.036 —59.4 12.3
Moderate carbamylation
4 80 0.063 0.080 —21.3
5 80 0.100 0.077 +29.9
6 80 0.087 0.056 +55.4
7 80 0.096 0.073 +31.5
8 78 0.310 0.246 +26.0
9 78 0.384 0.253 +51.8
10 75 0.090 0.077 + 16.9
11 75 0.284 0.167 +70.1
12 69 0.092 0.079 +16.5
13 69 0.053 0.029 +82.8
Mean SD 76 4 0.156 0.121 0.144 0.080 +40.2 23.4
Extensive carbamylation
14 66 0.509 0.148 +243.9
15 66 0.318 0.156 +103.8
16 48 0.335 0.132 +153.8
17 45 0.509 0.080 +536.3
18 45 0.129 0.053 +143.4
19 40 0.323 0.055 +487.3
20 40 0.064 0.034 +88.2
Mean SD 50 11 0.312 0.170 0.094 0.050 +251.0 185.5
minor modification, the extensive carbamylation of LDL mark-
edly accelerated LDL clearance from rabbit plasma. This
enhancement in LDL clearance was observed despite the fact
that the heavily carbamylated LDL showed only poor binding
to the LDL B/E receptors.
Derivation of LDL apoB by acetic anhydride (acetylation)
blocks LDL degradation via the high affinity apoB/E-receptor
dependent pathway in human fibroblasts [19]. However, acety-
lated LDL is cleared rapidly from rat plasma by the macrophage
scavenger receptors (acetyl-LDL receptors) [20]. Also, some
other derivations of LDL such as diketene (acetoacetylated)
and malondialdehyde modified LDL are not degraded by the
LDL apoB/E receptors, but are rapidly taken up by the scav-
enger mechanism [21, 22]. In fact, acetoacetytated human and
rat LDL are cleared so rapidly from the rat plasma that over
80% of the acetoacetylated LDL disappears within 30 minutes
after the injection [23]. In accordance with these previous
findings, our studies showed that the heavily carbamylated
LDL could not bind to the LDL apoB/E receptors, and yet most
of it disappeared from the rabbit circulation extremely fast after
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Fig. 4. Comparison of the catabolism of control-LDL (E') and native-
LDL (A). After iodination the control-LDL was incubated in sodium
borate buffer without potassium cyanate for 60 minutes and the native-
LDL was kept at + 4°C. FCR = fractional catabolic rate.
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Table 3. Fractional catabolic rates (FCR) for the LDL isolated from
uremic patients and from a control subject
Rabbit
no.
Patient
no.
Plasma
urea
mmol/liter
FCR for FCR for
uremic-LDL control-LDL FCRdifference
%pools/hr
1
2
3
4
5
6
7
8
9
10
1
1
2
2
3
3
4
4
5
5
29.1
32.6
21.2
28.9
18.3
0.033 0.038
0.070 0.082
0.035 0.052
0.061 0.103
0.065 0.075
0.065 0.077
0.040 0.038
0.071 0.071
0.085 0.097
0.074 0.083
—13.2
—14.6
—32.7
—40.8
—13.3
—15.6
+5.3
0.0
—12.4
—10.8
Each uremic-LDL and control-LDL was simultaneously injected into
two rabbits.
the injection. About 90% of the heavily carbamylated LDL was
cleared from rabbit plasma within two hours. Thus, it is
possible that the carbamyl-derived LDL could also be recog-
nized by the scavenger receptors resulting in a fast clearance
from the plasma.
Previous studies have demonstrated that even a small degree
of in vitro carbamylation of LDL decreased the ability of the
modified LDL to interact with the LDL apoB/E receptor on
human fibroblasts [24]. Experiments with LDL isolated from
uremic patients showed similar decrease in fibroblast binding
properties as carbamylated LDL [251.Moreover, studies on rat
peritoneal macrophages showed that it was necessary to car-
bamylate more than 12.5% lysine residues of LDL to stimulate
the scavenger receptors to recognize the modified LDL parti-
cles [24]. The studies also suggested that the same scavenger
receptor interacts with carbamylated LDL, acetylated LDL and
malondialdehyde-modified LDL [24]. However, uremic LDL
was not able to stimulate cholesterol ester accumulation within
macrophages similar to normal LDL [251. Overall, these data
are in agreement with our results that the binding of the
carbamylated LDL to the apoB/E receptors is reduced and also
suggest that only the heavily carbamylated LDL is recognized
by the scavenger receptors. The fact that both mildly and
heavily carbamylated LDL have reduced binding to the LDL
apoB/E receptors, but only the heavily carbamylated LDL is
recognized by the scavenger receptors, could also explain the
different clearance rates observed between the LDL prepara-
tions carbamylated to the various extents in our studies. How-
ever, other pathways must also be considered for the rapid
clearance of carbamylated LDL. For example, modification of
the lysine residues of LDL apoB with acetylation, ethylation,
methylation and, also with carbamylation, results in the pro-
duction of specific antibodies against the modified proteins [261.
These antibodies could form immunocomplexes that might be
removed rapidly from the circulation.
Can carbamylated LDL be generated in vivo? In carbamyla-
tion, urea-derived cyanate is formed by the spontaneous disso-
ciation of urea, and its reactive form (isocyanic acid) has been
reported to form covalent adducts with the amino groups of
various proteins [27]. Carbamylation of hemoglobin and pro-
teins in vitro by cyanate has been carefully explored [27—29].
The in vivo carbamylation of hemoglobin in uremic patients has
also been documented [6, 301. Because of the short half-life of
LDL in circulation the in vivo carbamyl-modification of LDL is
unlikely to be extensive enough to be taken up directly by the
scavenger receptor pathway. A minor carbamylation, however,
is possible in uremia. These minimally carbamylated LDL are,
according to our studies, cleared at a slower rate from the
plasma, and this increases the residence time of LDL in the
subendothelial region of the arteries. Our preliminary results on
the in vivo catabolism of the uremic-LDL demonstrate that
some alterations can be identified in the LDL of uremic
patients, resulting in the decreased catabolism of the uremic-
LDL. Whether this reduced clearance of uremic LDL is caused
by carbamylation or some other factors still remains unidenti-
fied. The increased residence time, however, may also subject
LDL to further modifications, including oxidation of LDL by
the interaction with endothelial cells [31] or binding of LDL to
glycosaminoglycans [321. Further detailed studies on the possi-
bility of carbamylation and/or other modifications of LDL in
vivo in uremia are urgently needed.
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